Recruiting

Testing a new insulin pump system for type 1 diabetes in real life

Plain-English translation of NCT07048795 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

What is this trial?

This trial is testing the mylife CamAPS FX system, which is a hybrid closed-loop insulin pump that works with a continuous glucose sensor to automatically adjust your insulin delivery. The study will follow 125 people with type 1 diabetes in France who are starting this new treatment to see how well it controls blood sugar and improves their daily life. This is being done in real-world conditions—meaning your regular doctor's office, not just a research lab.

The French health system approved this medication for insurance coverage, and they want to make sure it actually works well and improves quality of life for patients using it in everyday situations, not just in clinical trials.

Do you qualify?

You likely qualify if…

you have type 1 diabetes
you have been using a continuous glucose sensor (Dexcom or Abbott Libre) for at least 14 days before starting the new pump, with at least 70% sensor coverage
your diabetes doctor has decided you should start the mylife CamAPS FX system
you are able to read, understand, and complete questionnaires in French (or a parent can do this for you if you are a minor)
you have given informed consent to participate and allow your personal data to be used in the study

You likely don't qualify if…

you have used any closed-loop insulin pump system (including DIY systems) within the past 6 months
you are currently in another clinical trial or were in one within the past month
you have an active skin condition (like psoriasis, dermatitis, or infection) where the sensor or pump tubing would be placed
you have unstable diabetic eye disease that requires laser treatment
you are planning to move away within 12 months and won't be able to follow up at the study center

What participation looks like

You will start using the mylife CamAPS FX pump system combined with the Dexcom G6 glucose sensor under the care of your diabetes specialist. Over the course of the study, you'll complete online questionnaires about your blood sugar control and quality of life, and your doctor will monitor how well the system is working for you in your everyday life. The study is designed to follow your real experience—going to work, school, exercising, and managing diabetes as you normally would.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(22 sites)

France

CHU Amiens, Amiens

Hôtel Dieu-Pédiatrie, Angers

CH Victor Dupouy, Argenteuil

Hôpital Bois Guillaume, Bois-Guillaume

CHU de Bordeaux, Bordeaux